First-Line Treatment of Suspected MRSA
For suspected MRSA infections, the first-line treatment depends critically on the clinical presentation: for outpatient skin and soft tissue infections (SSTI), use oral clindamycin, TMP-SMX, or doxycycline; for hospitalized patients with complicated SSTI or invasive disease, use IV vancomycin.
Treatment Algorithm by Clinical Scenario
Outpatient SSTI with Suspected MRSA
Purulent cellulitis or abscess requiring antibiotics:
- First-line oral options 1:
- Clindamycin 300-450 mg PO three times daily (A-I evidence)
- TMP-SMX 1-2 double-strength tablets twice daily (A-II evidence)
- Doxycycline 100 mg twice daily (A-II evidence)
- Linezolid 600 mg twice daily (A-II evidence, but more expensive)
Key decision point: If you need coverage for both MRSA and β-hemolytic streptococci, use clindamycin alone OR combine TMP-SMX/doxycycline with amoxicillin 1.
Duration: 5-10 days, adjusted based on clinical response 1.
Hospitalized Patients with Complicated SSTI
For severe infections requiring IV therapy 1:
- IV vancomycin (A-I evidence) - remains the gold standard
- Linezolid 600 mg IV/PO twice daily (A-I evidence)
- Daptomycin 4 mg/kg IV once daily (A-I evidence)
- Telavancin 10 mg/kg IV once daily (A-I evidence)
- Clindamycin 600 mg IV three times daily (A-III evidence)
Duration: 7-14 days, individualized based on response 1.
Nonpurulent Cellulitis
Initial approach: Start with β-lactam therapy (e.g., cefazolin) for presumed streptococcal infection 1. Add MRSA coverage only if the patient fails to respond to β-lactam therapy or presents with systemic toxicity 1.
Critical Clinical Distinctions
Abscess management: Incision and drainage is the PRIMARY treatment 1. Antibiotics are indicated only when:
- Severe/extensive disease with multiple sites
- Rapid progression with associated cellulitis
- Signs of systemic illness
- Comorbidities or immunosuppression
- Extremes of age
- Difficult-to-drain locations (face, hand, genitalia)
- Septic phlebitis
- Failure of I&D alone 1
Pediatric Modifications
- Vancomycin 15 mg/kg/dose IV every 6 hours for hospitalized children with complicated SSTI 1
- Clindamycin 10-13 mg/kg/dose every 6-8 hours (max 40 mg/kg/day) if clindamycin resistance <10% 1
- Avoid tetracyclines in children <8 years 1
- Avoid TMP-SMX in infants <2 months and third-trimester pregnancy 1
Important Caveats
Vancomycin concerns: While vancomycin remains guideline-recommended first-line therapy for serious MRSA infections 1, emerging evidence suggests limitations including nephrotoxicity, difficulty achieving target levels, and treatment failures with higher MICs 2, 3, 4, 5. Recent network meta-analysis shows linezolid may have superior clinical success rates compared to vancomycin for MRSA infections 2, though vancomycin retains its guideline-supported position.
Rifampin warning: Never use rifampin as monotherapy or adjunctive therapy for SSTI 1.
Clindamycin resistance: Be aware of local resistance patterns. Inducible clindamycin resistance may still allow use in mild infections but should preclude use in serious infections 1.
Culture guidance: Always obtain cultures from purulent infections when treating with antibiotics, especially in severe cases, treatment failures, or suspected outbreaks 1.